Interleukin Genetics Appoints Partha P. Paul, Ph.D., as Senior Director, Business Development
08/05/2008
Interleukin Genetics Appoints Partha P. Paul, Ph.D.,
as Senior Director, Business Development
Waltham, MA – August 5, 2008 – Interleukin Genetics, Inc. (AMEX:ILI), today announced that Partha P. Paul, Ph.D., has joined the Company as Senior Director, Business Development. Dr. Paul will be responsible for all business development activities for Interleukin Genetics and will be reporting to the Chief Executive Officer, Lewis Bender. Dr. Paul brings to the firm extensive business development, as well as 15 years of industry related experience.
Prior to joining Interleukin Genetics, Dr. Paul was the Senior Director of Business Development at AtheroGenics, Inc., a publicly traded biotechnology company located in Georgia. He was responsible for negotiating and closing a number of significant partnering deals for AtheroGenics, including the $1 billion deal with AstraZeneca for the development and commercialization of a cardiovascular product. Prior to joining AtheroGenics, Dr. Paul was a Senior Research Scientist at Southwest Research Institute (SwRI), a contract research organization. While at SwRI, he had dual responsibilities in research and business development. As part of his revenue generation responsibilities, Dr. Paul established a number of industrial and governmental collaborations which brought the company millions of dollars in funding and contracts.
Dr. Paul holds a Ph.D. degree in biochemistry from Johns Hopkins University, Baltimore, MD, an M.B.A. in finance from Our Lady of the Lake University, San Antonio, TX and a M.Sc. in chemistry from Indian Institute of Technology, Kanpur, India.
About Interleukin Genetics
Interleukin Genetics, Inc. (AMEX:ILI), is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics currently offers an array of Nutraceuticals and OTCeuticals®, including Ginkoba®, Ginsana® and Venastat® which are sold at the nation’s largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics, its products and ongoing programs, please visit www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
# # #
Contacts:
Media:
Lisa Rivero
LaVoie Group
978-745-4200 x106
lrivero@lavoiegroup.com
Investor Relations:
Melanie Friedman
Stern Investor Relations
212-362-1200
melanie@sternir.com